Maternal methadone dosage and neonatal withdrawal

Area of Science:

• Obstetrics and Gynecology
• Neonatal Medicine
• Pharmacology

Background:

• Neonatal Abstinence Syndrome (NAS) is a significant concern in infants exposed to substances in utero.
• Opioid substitution therapy, such as methadone, is used to manage maternal substance use disorder during pregnancy.
• Understanding the dose-dependent effects of maternal methadone on neonatal outcomes is crucial for clinical management.

Purpose of the Study:

• To investigate the relationship between maternal methadone dosage and the severity of neonatal withdrawal symptoms.
• To determine if higher maternal methadone doses correlate with increased NAS severity, longer hospitalizations, and prolonged treatment durations.

Main Methods:

• Retrospective chart review of 67 drug-abusing mothers and their 70 infants.
• Analysis of documented drug usage patterns and neonatal withdrawal severity using the Neonatal Abstinence Score (NAS).
• Comparison of outcomes between infants whose mothers received methadone versus those who did not, and correlation with methadone dosage.

Main Results:

• A strong positive correlation was found between maternal methadone dose at delivery and neonatal withdrawal severity.
• Infants of mothers on methadone had significantly higher mean peak symptom scores ( > 10) compared to the no-methadone group ( < 4).
• Increasing maternal methadone doses were associated with statistically significant increases in length of hospital stay and duration of neonatal treatment (p < 0.001).

Conclusions:

• Maternal methadone dosage is a critical factor influencing the severity of neonatal withdrawal.
• Higher methadone doses in pregnant women are linked to more severe NAS and increased resource utilization.
• Clinical guidelines should consider maternal methadone dosage when managing pregnant women with opioid use disorder and their neonates.